Aptcash Enterprises
Parel, Mumbai, Maharashtra
SEND SMS
SEND EMAIL

Oncquest laboratory ltd

Diagnostic center is a place where different medical examinations are carried. A diagnosis or medical examinations are done on patient to check whether the body is carrying any disease or symptoms. Based on the diagnosis, treatment is given to the patient accordingly.

Oncquest is a well known testing lab which has its Pathology diagnostic labs in Mumbai and other parts of India. We at Oncquest are delivering over 30 million tests a year, catering to more than 20,000 medical Laboratories, Hospitals, Nursing homes and 2,00,000 Consultants.

We are a dynamic and constantly improving laboratory center, providing reliable pathology services to our clients and patients. We strive to produce extremely satisfactory results by keeping in touch with the latest developments in the field of pathology

We implement the latest technology available and our labs are equipped with molecular technology including fields such as bioinformatics, pharmocogenomics, companion diagnostics, proteomics and biomarker studies. We are also equipped with an integrated research facility and an advanced genetic oncology wing, thus expanding our scope of testing.

We are a certified and accredited cancer diagnosis lab by the National Accreditation Board for Testing and Calibration Laboratories (NABL) and College of American Pathology (CAP).

Oncquest Laboratories Ltd. – Mumbai

FoundationOne Heme

Approx. Price: Rs 3.1 Lakh / testGet Latest Price
What is FoundationOne Heme?

FoundationOne Heme is a comprehensive genomic profiling test for hematologic malignancies and sarcomas. The test is designed to provide physicians with clinically actionable information to help with diagnostic subclassification, prognosis assessment, and targeted therapeutic selection. Test results provide information about clinically relevant alterations, potential targeted therapies, available clinical trials, and quantitative biomarkers that may support immunotherapy clinical trial enrollment.

FoundationOne Heme is validated to detect the four main classes of genomic alterations in more than 400 cancer-related genes. In addition to DNA sequencing, FoundationOne Heme employs RNA sequencing across more than 250 genes to capture a broad range of gene fusions, common drivers of hematologic malignancies, and sarcomas.

  • >400

    genes interrogated

  • >30

    select introns profiled

  • >250

    RNA-sequenced genes

  1. A single test that detects the four main classes of genomic alterations for hematologic cancers and sarcomas
  2. Uses both DNA and RNA sequencing for sensitive detection of translocations and fusions
  3. Reports tumor mutational burden (TMB) and microsatellite instability (MSI), which may inform clinical decision making and clinical trial enrollment

 

Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 test
Get Best Quote
Yes! I am Interested

BRCA 1 & 2 comprehensive

Approx. Price: Rs 20,000 / cancer testGet Latest Price

BRCA1 & BRCA2 are  genes that produce tumor suppressor proteins & play a role in ensuring the stability of the cell’s genetic material.

Clinical Utility

  • Provide a better measure of the cancer risk .
  • Allow a clinician to tailor cancer screening as needed.
  • Help in choosing surgery or chemotherapy

Key Benefits

  • The reporting will be done as per AMCG (American College of Medical Genetics) guidelines. The guidelines attached for your reference.
  • The test is based on sequencing of all the exons (in both directions) as well as highly conserved intron-exon splice junctions. Hence, the test is able to detect the mutations whether they were reported in the past or not.
  • All the gene mutations clinically related to disease will be reported if they are present in the specific patient sample (as Class 6). As per ACMG guidelines, the polymorphisms or SNPs that are commonly known to be benign are not reported.
  • The report indicates the reference sequence and version number for example NM_007294.3.
  • The report provides the Pubmed ID of the reference (PMID), on which the interpretation was made, in case of pathogenic variations . The references are also cited for specific variation described and the clinician can check this reference easily.
  • Significantly reduce medical costs through earlier diagnosis and treatment of cancer.
  • Knowing the test results may benefit family members as well.
Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 cancer test
Get Best Quote
Yes! I am Interested
View PDF

MammaPrint Test Combination

Approx. Price: Rs 3.5 Lakh / Cancer Laboratories testGet Latest Price

The MammaPrint is a genomic test that analyzes the activity of certain genes in early-stage breast cancer. The MammaPrint Test is used in two ways:

  • Research suggests the MammaPrint test eventually may be used to estimate a woman’s recurrence risk for early-stage breast cancer that is hormone-receptor-positive or hormone-receptor-negative.
  • The MammaPrint test analyzes 70 genes using a microarray-based gene expression profile to see how active they are and then calculates either a high-risk or a low-risk recurrence score

Who’s eligible for the MammaPrint test?

MammaPrint can only be used to analyze early-stage breast cancers that are:

  • Stage I or stage II
  • Invasive
  • Smaller than 5 centimeters
  • Estrogen-receptor-positive or -negative

In both the United States and internationally, MammaPrint can be used to analyze cancers that are hormone-receptor-positive and hormone-receptor-negative.

How does the MammaPrint test work?

The MammaPrint test looks at the activity of 70 genes and then calculates a recurrence score that is either low risk or high risk.

If a patient decide to have the MammaPrint test, a patient and a patient’s doctor will consider a number of factors when deciding on whether to add chemotherapy to a patient treatment plan, including:

  • A patient age
  • The size of the cancer
  • Cancer grade
  • Whether cancer cells were found in nearby lymph nodes
  • A patient general health
Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 Cancer Laboratories test
Get Best Quote
Yes! I am Interested

ROS1 GENE TESTING FOR LUNG CANCER

Product Price :Get Latest Price
ROS1 GENE TESTING FOR LUNG CANCER
  • ROS1 gene is a  proto-oncogene which belongs to the subfamily of tyrosine kinase insulin receptor genes.
  • ROS protein plays an important role in cell growth and cell specialization.
  • Mutations in the ROS1 gene can lead to a type of lung cancer known as non-small cell lung cancer (NSCLC)

Clinical Utility

  • ROS1 gene testing is done in patients who are ALK negative
  • Prognosis and prediction of response to Crizotinib.
  • Monitor progression of the disease in NSCLC patients.

Key Benefits

  • ROS1 gene mutation are more common in lung cancer patients who are non smokers and relatively young (average age of 50 years).
  • ROS1 mutations have been also linked to cholangiocarcinoma (bile duct cancer) and glioblastoma multiform, a type of brain cancer.

MET GENE TESTING FOR LUNG CANCER

  • The MET protein is a receptor kinase that stimulates tyrosine-kinase activity which leads to activation of signalling pathways associated with cell growth and survival.
  • MET protein over expression leads to tumor growth and unfavourable prognosis in patients with lung adenocarcinoma.

Clinical Utility

  • Met gene testing is done for the prognosis & cause of drug resistance to anti- EGFR TKI
  • Monitor progression of the disease in lung carcinoma patients.
  • Patients with non-small cell lung cancer and EGFR-activating mutations, which increase sensitivity to tyrosine kinase inhibitor (TKI) therapy, may be resistant to TKI therapy in the presence of MET oncogene amplification

Key Benefits

  • MET gene testing by Fish is a confirmatory technique used for the MET gene amplification.
  • It identifies a small but clinically important subgroup of gastric cancer patients who are likely to respond to MET-TKIs.
Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 cancer laboratory test
Ask For Price
Yes! I am Interested
View PDF

Foundation one (solid tumors)

Product Price :Get Latest Price
Foundation one (solid tumors)
  • Comprehensive genomic profile that interrogates the entire coding sequence of 315 cancer-related genes plus select introns from 28 genes often rearranged or altered in solid tumor cancers.
  • Identifies all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements.
  • Identify clinically relevant genomic alterations associated with targeted therapies
  • Quantify clinical markers associated with immunotherapy response
Foundation one  Heme (hematology malignancies & sarcomas)
  • Comprehensive genomic profile for hematologic cancers (leukemia, lymphoma and myeloma) and sarcomas.
  • Designed to provide physicians with clinically actionable information relevant for diagnosis, risk-stratification and prognosis to guide treatment options for patients based on the genomic profile of their cancer.
  • Assess routine cancer specimens for all genes that are currently known to be somatically altered in hematologic malignancies and sarcomas.
  • Simultaneously detects all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements in 405 cancer-related genes.
  • Also employs RNA sequencing across 265 genes to capture a broad range of gene fusions, a type of alteration that is a common driver of hematologic cancers and sarcomas.
Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 cancer laboratories test
Ask For Price
Yes! I am Interested

CIRCULATING TUMOR CELLS

Product Price :Get Latest Price
CIRCULATING TUMOR CELLS

A circulating tumor cell has sloughed off cancerous tissue and moves through the bloodstream to a new site.

Circulating Tumor Cells Assay
  • CTC enumeration helps in determining the prognosis of a patient in metastatic breast, metastatic colon & metastatic prostate cancer. Falling CTCs after initiation of therapy indicates a better prognosis compared to where the counts are same or rising.
  • CTC is checked at three time points –before initiation of therapy, after completion of first cycle & one year later.
  • Defined threshold values for CTC counts for specified cancers such as Breast, Prostate, Colorectal cases, helps to assess disease status even at the baseline CTC count.
  • CTCs can be isolated for further molecular characterization so that the behavior of the tumor can be assessed in real time and  treatment can be planned accordingly.
  • Early detection of CTC helps to take interventional measures.
Benefits over PET/CT scan
  • CTC findings are available after the first cycle of chemotherapy or radiotherapy where as PET would take 2-3 months to show findings.
  • Detection of malignancy is not masked by inflammation/infection /healing tissue
  • Benign conditions are not misinterpreted as malignant
  • No radiation risk due to radioactive material
  • No restriction about tumor size
Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 cancer laboratories test
Ask For Price
Yes! I am Interested
View PDF

Panorama Test

Product Price :Get Latest Price
Panorama Test

Panorama is the most advanced Non-Invasive Pre Natal Test(NIPT) performed on maternal blood to screen the most common fetal chromosome abnormalities such as  t21, t18, t13, Monosomy X, Triploidy and Microdeletions.

Clinical Utility

  • Identifies Trisomy 21, 13,&  18, Monosomy X, Triploidy  & Micro deletions.
  • Can differentiate between Maternal & Fetal DNA.
  • The test can be used as early as 9 weeks of gestation.

Key Benefits

  • Most advanced pre natal test.
  • Only NIPT screen test that can identifies Triploidy.
  • The test is accurate even at fetal fractions as low as 4%.
  • Only NIPT test that uses SNPs(Single Nucleotide Polymorphisms) to differentiate maternal from the fetal DNA.
  • Sensitivity & Specificity >99%
Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 Pre Natal Test(NIPT)
Ask For Price
Yes! I am Interested
View PDF

Cancer HOT SPOT Panel (50 Genes by NGS)

Product Price :Get Latest Price
Cancer HOT SPOT Panel – 50 Genes by NGS
  • Allows translational and disease researchers to fast track oncology research by surveying hotspot regions of 50 oncogenes and tumor suppressor genes with wide coverage of many genes including KRAS, BRAF and EGFR genes.
  • Breakthrough technology with improved primer design, containing 207 primer pairs in a single tube and requires as little as 10ng of DNA, enabling researchers to sequence challenging samples such as formalin-fixed and paraffin-embedded (FFPE) tissue (, which are typically available only in small amounts and often exhibit variable quality).
  • Help in targeted therapy, reducing costs and improving the outcome of therapy
  • Very significant in cases where the patient has failed 1st / 2nd line of therapy or there has been no actionable mutation from the preliminary testing
  • A comprehensive information of the actionable mutations at the outset can help in timely treatment
    Helpful when trying to enrol the patient for clinical trials

Next Generation Sequencing (NGS)

A highly sensitive technology, which can detect mutations in samples having as low as 5% tumor cells. It can be multiplexed that is many genes can be targeted at the same time, thus detecting various mutations in the same assay. Each DNA nucleotide is read several times (100-1000 times) which adds to the specificity of the assay. This platform provides accurate, reliable data and excellent coverage.

Advantages of NGS

  • All at Once Approach for Cancer Diagnostics
  • NGS captures a broader spectrum of mutations
  • Comprehensive view of the most “actionable mutations” in solid tumors with greater in depth coverage,
    thus leading to enhanced sensitivity
  • The increased sensitivity of NGS allows detection of mosaic mutations
  • As low as 5% of mutant DNA can be detected, hence very low amount of DNA (~10 -50ng) as specimen is required
  • Faster TAT as compared to sequential gene testing using conventional methods
Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 cancer laboratories test
Ask For Price
Yes! I am Interested
View PDF

Cancer Blood / Laboratory Test

Product Price :Get Latest Price

“World class facilities available under one roof”
Oncquest has one of the widest test portfolios in the diagnostic industry especially in exploratory & end-point biomarkers, genomic services & histology. Our ten years of molecular testing experience & accomplishments has enabled us to adapt to market trends & customer requirements and hence have been able to develop tests based on the protocol requirements. Our encouraging team & flexible organizational structure equips us to evaluate exploratory biomarkers. We develop & validate biomarkers based on wide range of technologies possessed by Oncquest. We have launched many molecular tests in Indian market.Read More

Specialised Services –

Oncquest offers more than 1000 assays spanning the screening, diagnostic, monitoring and prognostic spectra of laboratory assays from Oncology to Infectious diseases on the Quality guidelines of NABL and College of American Pathologists (CAP).

Our Specialised Capabilities are:– Molecular Pathology

  • PCR
  • Gene Sequencing

– Cytogenetics and FISH

– Haematology & Flow Cytometry

– Immunohistochemistry (IHC)

– Surgical Pathology

– Next Generation Sequencing(NGS)

To view other details, Please click here.

General Pathology –

Oncquest offers more than 1000 assays for clinical diagnosis spanning diagnostic, monitoring and prognostic spectra of assays for all your
needs.

 

Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 cancer laboratories test
Ask For Price
Yes! I am Interested

NSCLC (Non-small cell lung cancer) Panel:3

Product Price :Get Latest Price
Test Detail : EGFR by ARMS PCR; ALK by IHC; ROS1 by FISH
Technique : ARMS PCR & IHC & FISH
Specimen : FFPE tissue block
Temperature : Ambient Temperature
Special Instructions for Sample Collection : Brief clinical history mandatory
Run days at Section : Every day if received before 1:00 p.m.
TAT / Reported on : 5th working day if received before 1200hrs
Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 Cancer Laboratories Test
Ask For Price
Yes! I am Interested

ImuPro Complete 270 trigger food items

Product Price :Get Latest Price
ImuPro Complete 270 trigger food items
Test Detail :
Technique : ELISA
Specimen : 8ml of blood is collected. 4ml Serum? to kept in 2 separate tubes, 2 ml each.
Temperature : 2-8℃
Special Instructions for Sample Collection : Sample can be collected anytime during the day after 3 hour fasting
Run days at Section : Every day if received before 1:00 p.m.
TAT / Reported on : 14th working day by 7:00 p.m.
Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 Imupro Diet test
Ask For Price
Yes! I am Interested

CanAssist-breast -an immunohistochemistry based test

Product Price :Get Latest Price
CanAssist-breast -an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: a cost-effective and...
Date24 November 2018
EventESMO Asia 2018 Congress
SessionPoster display - Cocktail
TopicsBioethics, Legal, and Economic Issues
Personalised/Precision Medicine
Breast Cancer
Pathology/Molecular Biology
PresenterManjiri Bakre
CitationAnnals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426
AuthorsM. Bakre   Author Affiliations
Abstract Background

Current molecular risk stratification tests have helped clinicians to optimize chemotherapy for hormone receptor positive, HER2 negative early stage breast cancer patients leading to huge savings in treatment costs and improved quality of life. However, current tests are not impactful in the Asian subcontinent due to the extreme cost-sensitivity of the market. Aim of this study was to develop and validate a simple, cost-effective and accurate test based on insightful biomarkers involved in tumor recurrence using robust statistical methodology to stratify patients based on risk of recurrence.

Methods

A retrospective cohort of 300 patients, was used to develop ‘CanAssist-Breast’(CAB)- an immunohistochemistry based test comprising 5 biomarkers plus three clinical parameters (Tumor size, node status and grade) using machine learning based algorithm. Retrospective clinical validation on 850+ cases was performed and Kaplan Meier survival analysis, multivariate analysis was performed to assess robustness of the test.

Results

CanAssist-Breast classifies patients into ‘low or high’ risk of recurrence based on recurrence score on a scale of 1-100 with a cut off at 15.5. Clinical validation of CAB showed distant metastasis-free survival (DMFS) was significantly different between low- (DMFS: 95%) and high-risk (DMFS 80%) groups in the validation cohort treated with hormone therapy alone (n = 195) and in the entire validation cohort of 857 patients as well. In multivariate analysis, CAB risk score was the most significant independent predictor of distant recurrence with a hazard ratio of 4.25 (P = 0.009). Patients stratified as high-risk by CAB have 19% chemotherapy benefit. We also show that CAB can further identify discrete low- and high-risk sub-groups within IHC4 intermediate risk group and also in a node and age independent manner.

Conclusions

To our knowledge, CAB is the first machine learning based prognostic risk of recurrence prediction classifier using a combination of unique biomarkers and clinicopathological parameters. We believe that CAB enables accurate treatment planning in early stage HR+/HER2- breast cancer patients in low-resource settings.

Editorial acknowledgementClinical trial identificationLegal entity responsible for the study

OncoStem Diagnostics.

Request
Callback


Additional Information:

  • Minimum Order Quantity: 1 Cancer Laboratories Test
Ask For Price
Yes! I am Interested

Foundation one

Product Price :Get Latest Price
FoundationOne® is a fully informative Comprehensive Genomic Profile from Foundation Medicine, Inc. that complements traditional cancer treatment decision tools. FoundationOne® often expands treatment options by matching patients with targeted therapies and clinical trials that are relevant to the molecular changes in their tumor based on the most recent scientific and medical published evidence. Results are provided in a user-friendly interpretive report. FoundationOne® utilizes proprietary next-generation sequencing techniques to identify all classes of alterations in genes known to be somatically altered in solid tumor cancers.

Foundation one (solid tumors)
  • Comprehensive genomic profile that interrogates the entire coding sequence of 315 cancer-related genes plus select introns from 28 genes often rearranged or altered in solid tumor cancers.
  • Identifies all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements.
  • Identify clinically relevant genomic alterations associated with targeted therapies
  • Quantify clinical markers associated with immunotherapy response

    Foundation one Heme (hematology malignancies & sarcomas)
    • Comprehensive genomic profile for hematologic cancers (leukemia, lymphoma and myeloma) and sarcomas.
    • Designed to provide physicians with clinically actionable information relevant for diagnosis, risk-stratification and prognosis to guide treatment options for patients based on the genomic profile of their cancer.
    • Assess routine cancer specimens for all genes that are currently known to be somatically altered in hematologic malignancies and sarcomas.
    • Simultaneously detects all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements in 405 cancer-related genes.
    • Also employs RNA sequencing across 265 genes to capture a broad range of gene fusions, a type of alteration that is a common driver of hematologic cancers and sarcomas.
    Request
    Callback


    Additional Information:

    • Minimum Order Quantity: 1 cancer laborotories test
    Ask For Price
    Yes! I am Interested
    X

    Explore more products



    Reach Us
    Deepak More (Proprietor)
    Shop No. 7, Nirmala Niwas, Aai Mai Merwanji Road Parel
    Mumbai- 400012, Maharashtra, India



    Call Us

    Share Us

    F GT L


    Send E-mailSend SMS